Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z009
- Development stage
- Preclinical
- Lead developer
- Ziphius Vaccines
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Z009 is a self-amplifying RNA (saRNA) vaccine candidate developed by Ziphius for the prevention of Chlamydia trachomatis infection. The vaccine leverages Ziphius's proprietary saRNA technology, which incorporates an alphavirus-derived replicase to enable the intracellular replication of the RNA template. This mechanism allows for sustained expression of the encoded Chlamydia trachomatis antigens, aiming to induce a robust and durable immune response while requiring a lower dose compared to traditional mRNA vaccines. Z009 is currently in the preclinical stage of development.
02
Targets
Beyond the preview
Go deeper on Z009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Z009.